| Schedule of Deferred Tax Assets and Liabilities [Table Text Block] |
| | | 2021 | | | 2020 | | | Deferred tax assets: | | | | | | | | | | Net operating loss carryforward | | $ | 18,449,694 | | | $ | 14,737,240 | | | Research and development tax credit carryforward | | | 1,566,293 | | | | 1,189,110 | | | Stock-based compensation expense | | | 129,475 | | | | 4,870 | | | Accrued salaries | | | 69,940 | | | | 72,721 | | | Total deferred tax assets | | | 20,215,402 | | | | 16,003,941 | | | Deferred tax liabilities | | | | | | | | | | Depreciation | | | 30,945 | | | | 28,274 | | | Net deferred tax assets | | | 20,184,457 | | | | 15,975,667 | | | Valuation allowance | | | (20,184,457 | ) | | | (15,975,667 | ) | | Net deferred tax asset after reduction for valuation allowance | | $ | -0- | | | $ | -0- | | |
| Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] |
| | | 2021 | | | 2020 | | | U.S. federal statutory rate applied to pretax loss | | $ | (3,899,767 | ) | | $ | (621,194 | ) | | Permanent differences | | | - | | | | 65 | | | Research and development credits | | | (377,183 | ) | | | (66,574 | ) | | Change in valuation allowance, net of expired items and other adjustments | | | 4,276,950 | | | | 687,703 | | | Reported income tax expense | | $ | -0- | | | $ | -0- | | |